Back
Justice Delayed: Addressing Pricing Of Lifesaving Cancer Medications
In the hallowed halls of the judiciary, the phrase
"justice delayed is justice denied"
is often invoked as a cautionary principle. However, for a deceased bank employee who sought to make life-saving breast cancer treatment affordable for thousands, this old adage has transformed into a grim reality. A
originally filed in
regarding the exorbitant pricing of patented breast cancer medications, specifically Ribociclib and Abemaciclib, has been listed for a
an agonizing 57 times without reaching a verdict. Since
, the matter has languished in procedural flux—a situation that has now prompted an urgent representation to the Chief Justice of the
, Soumen Sen, calling for immediate administrative and judicial intervention.
The Litigant’s Fight and the Institutional Response
The legal battle began with a simple, desperate plea: a patient suffering from invasive breast cancer, facing the prohibitive costs of targeted therapy—ranging from Rs. 47,000 to over Rs. 95,000 per month—approached the court seeking state intervention. She specifically requested the government to invoke "" licenses under , to allow for the domestic production of generic alternatives at a fraction of the cost.
Tragically, the petitioner succumbed to her illness while the litigation was still in its infancy. Yet, the gravity of the public health crisis prompted the to take cognizance, keeping the case alive under the title . Despite this noble continuation, the case has been subject to a staggering 40 adjournments, circulating through the chambers of eight different judges across 58 postings. As researchers and the have noted, the human cost of these delays is not merely theoretical; it is a profound failure of the judicial process to address the fundamental rights of citizens in need.
The Core of the Dispute: Patent Law vs. Fundamental Rights
At the heart of the legal argument lies the interpretation of "." The Central Government, in its submissions, has historically resisted the issuance of licenses, arguing that the prevalence of specific breast cancer subtypes does not reach the threshold of defined public health crises. However, the legal community and public health advocates argue that this interpretation is overly restrictive.
The drugs in question, Ribociclib and Abemaciclib, are essential for treated non-metastatic and advanced breast cancers. With the (GLOBOCAN) estimating more than 1.9 lakh new breast cancer cases in India annually, the reliance on patent protection for such expensive, targeted therapies effectively marginalizes the vast majority of the population. The legal contention remains: does the State’s duty to protect the "Right to Life" under supersede the commercial monopoly granted by the Patents Act? The High Court’s current struggle illustrates the difficulty in balancing intellectual property protections with the constitutional mandate to ensure access to healthcare.
The Anatomy of Procedural Failure
The letter addressed to Chief Justice Soumen Sen, authored by and of the , serves as a searing critique of current procedural bottlenecks. When pleadings are complete, stakeholders have been heard, and the issue is clearly articulated as being of "larger public interest," the utility of 57 listings for a "" without a substantive outcome is increasingly difficult to justify.
The continuous rescheduling—often leading to the case being listed before different judges—destroys the continuity required for complex litigation. For the legal professional, this case serves as a disturbing case study in how "case management" can inadvertently become a tool for indefinite delay, particularly when high-stakes pharmaceutical interests are pitted against public health concerns. The fact that the matter remains pending despite the completion of all formal arguments suggests a lack of priority at the administrative level, which the Chief Justice is now being urged to rectify.
Impact on Legal Practice and Healthcare Litigation
The outcome of this case holds significant implications for the future of regarding healthcare. If the succeeds in streamlining the resolution of this matter, it could establish a precedent for how the judiciary handles cases requiring urgent state intervention in the market for essential medicines.
Conversely, if the status quo remains, it will likely discourage petitioners from seeking legal recourse through the courts for health-related grievances, reinforcing a belief that the judiciary is ill-equipped—or unwilling—to challenge corporate pharmaceutical interests in favor of public welfare. For attorneys specializing in health law, the lesson is clear: the procedural hurdles inherent in the system are as formidable as the substantive legal questions. Effective litigation in this field now requires not only brilliance in constitutional argument but also a persistent, often administrative, battle to keep a matter on the docket until it is ripe for a judgment.
Conclusion
The tragedy of the original petitioner, who passed away without seeing the fruits of her legal battle, is a stinging rebuke to the pace of our judicial system. The Working Group’s appeal is not just a request for a hearing date; it is a plea for the Court to exercise its authority to honor the dignity of those it serves. As the case reaches its 58th posting, the judiciary faces a reckoning. To fulfill the promise of providing
"hope to others who are suffering from the dreaded disease,"
the
must move beyond the cycle of endless interim orders and finally reach a substantive decision.
For the legal community, this case is an invitation to re-examine the structural deficiencies that lead to such prolonged delays. As counsel, judges, and administrative officers, the duty is to ensure that when citizens approach the court for access to life itself, the process does not become the very thing that denies them the justice they seek. The upcoming hearing provides a pivotal moment to restore faith in the judicial mechanism’s capability to stand as a bulwark for the vulnerable, not just an observer of their struggle.
